Cargando…
Outcome after single dose of ChAdOx1 vaccine against SARS-CoV-2 infection at 16 weeks post-vaccination among healthy adults in Saudi Arabia
BACKGROUND: The rate of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection and immunogenicity of a single dose of ChAdOx1 vaccine at 16 weeks post-vaccination among young and healthy participants remains unclear in Saudi Arabia. OBJECTIVES: Assess the rate of subsequent infection...
Autores principales: | Alghamdi, Ahlam, Alsanea, Nasser, Alraey, Mohammed, Joseph, Mercy, Aboud, Mohammed, Almangour, Thamer, Alharbi, Wasaef, Alhumidan, Hind, Alanizi, Abdalrhman, Al-jedai, Ahmed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
King Faisal Specialist Hospital and Research Centre
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357300/ https://www.ncbi.nlm.nih.gov/pubmed/35933607 http://dx.doi.org/10.5144/0256-4947.2022.223 |
Ejemplares similares
-
BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
por: Alghamdi, Ahmed N., et al.
Publicado: (2021) -
Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021) -
Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023) -
Inflammatory myositis after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2021) -
ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)